Formycon Valuation
Is FYB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of FYB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FYB?
Other financial metrics that can be useful for relative valuation.
| What is FYB's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €690.51m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.7x |
| Enterprise Value/EBITDA | -298.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does FYB's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.4x | ||
BIO3 Biotest | 1.7x | 2.0% | €1.4b |
MOR MorphoSys | 10.7x | 21.9% | €2.5b |
HPHA Heidelberg Pharma | 14.4x | 21.2% | €141.7m |
MDG1 Medigene | 7x | 18.6% | €42.2m |
FYB Formycon | 10.1x | 25.0% | €690.5m |
Price to Earnings Ratio vs Industry
How does FYB's PE Ratio compare vs other companies in the DE Biotechs Industry?
Price to Sales Ratio vs Fair Ratio
What is FYB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 10.1x |
| Fair PS Ratio | 3x |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?